Michelle T. Long, MD, MSc
Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Preventive Medicine & Epidemiology

MD, Tufts University School of Medicine
MSc, Boston University School of Public Health
BA, Middlebury College

Pronouns: she/her/hers



Michelle T. Long, MD, MSc is a physician-scientist with an expertise in Nonalcoholic fatty liver disease (NAFLD), and an Associate Professor of Medicine at Boston University. She completed her clinical training at Massachusetts General Hospital and Boston Medical Center. Dr. Long is the Director of the NAFLD Research Center and the Director of Clinical Research for the Section of Gastroenterology and Hepatology. Her clinical and research interests center on the relationship between NAFLD and cardiovascular disease. Dr. Long is primarily interested in patient-oriented research investigating fibrosis and inflammation in patients with NAFLD and in imaging and risk stratification strategies for hepatic fibrosis. Dr. Long has projects at Boston Medical Center and at the Framingham Heart Study where she is the PI of a study evaluating the prevalence and risk factors for liver fat (steatosis) and fibrosis. In Framingham, she is investigating the clinical and genetic correlates of hepatic steatosis and fibrosis as measured by transient elastography. Dr. Long receives research funding from the NIH (NIDDK), Doris Duke Charitable Foundation, Gilead Sciences, Echosens Corporation, and Boston University. She has expertise in epidemiology, visceral fat, liver imaging including computed tomography, ultrasound, and transient elastography. Dr. Long is also a clinical hepatologist and endoscopist.

Dr. Long is additionally interested in novel therapeutics for NAFLD and Non-alcoholic steatohepatitis (NASH) and runs the clinical trials program for the NAFLD Research Center.

Her other research interests include alcohol-related liver disease, hepatitis C, outcomes in end-stage liver disease/cirrhosis.

Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Gastroenterology

Investigator
Framingham Heart Study


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Full Member
Boston University Medical Center
Boston Nutrition Obesity Research Center




Resting metabolic signature of non-alcoholic fatty liver disease and the metabolic response to acute exercise in a community based sample
07/01/2019 - 08/05/2022 (PI)
Doris Duke Charitable Foundation


Prevalence and risk factors for hepatic steatosis and fibrosis as measured by transient elastography
03/15/2016 - 05/31/2019 (PI)
Echosens



NATiV3: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stag
05/17/2022 - 05/17/2029 (PI)
Inventiva S.A.


A Phase 1, Double Blind, Randomised, Placebo-controlled, Multi-centre, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2693 in Patients with Non-alcoholic Steatohepatitis (NASH) with Fibrosis S
12/01/2021 - 11/30/2024 (PI)
Astrazeneca Pharmaceuticals


A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients with Presumed Non-Cirrhotic
09/08/2020 - 07/31/2023 (PI)
Terns Pharmaceuticals, Inc.


AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
07/01/2019 - 07/31/2023 (PI)
Allergan Sales, LLC


MB130-068
12/06/2018 - 03/31/2023 (PI)
Bristol-Myers Squibb Company


Non-alcoholic Steatohepatitis (NASH) and Stage 3 or Stage 4 Liver Fibrosis
01/15/2020 - 01/14/2023 (PI)
Celgene


Identifying clinical and genetic correlates of hepatic fibrosis from fatty liver disease in the…
01/12/2018 - 08/05/2022 (PI)
National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
5K23DK113252-03

Determining the burden, heritability, and clinical implications of increased liver stiffness from…
01/02/2019 - 12/31/2021 (PI)
Gilead Sciences


MB130-069
12/06/2018 - 12/06/2021 (PI)
Bristol-Myers Squibb Company


A Double-Blind, Placebo-Controlled Trial of Obeticholic Acid in Patients with moderately severe A…
10/06/2016 - 10/05/2018 (PI)
Indiana University NIH-NIAAA
4U01AA021840-05


Title

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. El-Sabawi B, Tanriverdi K, Gajjar P, Nayor M, Landman JM, Below JE, Haff M, Long M, Ezpeleta M, Freedman JE, Varady K, Shah R, Perry AS. Circulating Proteomics Identifies a Dynamic Profile of Hepatic Steatosis During Metabolic Intervention. J Am Heart Assoc. 2025 May 15; e037100.View Related Profiles. PMID: 40371575
     
  2. Mohanty A, Austad K, Bosch NA, Long MT, Nolen-Doerr E, Walkey AJ, Drainoni ML, Rizo I, Fantasia KL. Assessing Clinician Engagement with a Passive Clinical Decision Support System for Liver Fibrosis Risk Stratification in a Weight Management Clinic. Endocr Pract. 2025 Apr 25.View Related Profiles. PMID: 40288606
     
  3. Newsome P, Sanyal A, Kliers I, Østergaard L, Long M, Kjær M, Cali AMG, Bugianesi E, Rinella M, Roden M, Ratziu V. Erratum: Late breaking abstracts. Hepatology. 2025 Apr 21. PMID: 40258120
     
  4. Fuster D, So-Armah K, Cheng DM, Blokhina E, Patts G, Lioznov D, Gnatienko N, Long MT, Freiberg MS, Tindle H, Samet JH. Is There an Association Between Cigarette Smoking and Advanced Liver Fibrosis in Smokers with HIV, Heavy Drinking and High Prevalence of HCV? J Clin Med. 2025 Feb 11; 14(4).View Related Profiles. PMID: 40004700; PMCID: PMC11856725; DOI: 10.3390/jcm14041169;
     
  5. Sun N, Prescott B, Ma J, Xanthakis V, Quatromoni PA, Long MT, Walker ME. The cross-sectional association between ultra-processed food intake and metabolic dysfunction-associated steatotic liver disease. Clin Nutr ESPEN. 2025 Apr; 66:215-220.View Related Profiles. PMID: 39880205; DOI: 10.1016/j.clnesp.2025.01.045;
     
  6. Florea VV, Gajjar P, Huang S, Tang J, Zhao S, Davenport M, Mi MY, Haff M, Zhang X, Miller PE, Vasan RS, Liu CT, Lewis GD, Shah RV, Long MT, Nayor M. Hepatic Steatosis and Fibrosis, Cardiorespiratory Fitness, and Metabolic Mediators in the Community. Liver Int. 2025 Jan; 45(1):e16147.View Related Profiles. PMID: 39673712; PMCID: PMC11649011; DOI: 10.1111/liv.16147;
     
  7. Feng G, Targher G, Byrne CD, Yilmaz Y, Wai-Sun Wong V, Adithya Lesmana CR, Adams LA, Boursier J, Papatheodoridis G, El-Kassas M, Méndez-Sánchez N, Sookoian S, Castera L, Chan WK, Ye F, Treeprasertsuk S, Cortez-Pinto H, Yu HH, Kim W, Romero-Gómez M, Nakajima A, Win KM, Kim SU, Holleboom AG, Sebastiani G, Ocama P, Ryan JD, Lup?or-Platon M, Ghazinyan H, Al-Mahtab M, Hamid S, Perera N, Alswat KA, Pan Q, Long MT, Isakov V, Mi M, Arrese M, Sanyal AJ, Sarin SK, Leite NC, Valenti L, Newsome PN, Hagström H, Petta S, Yki-Järvinen H, Schattenberg JM, Castellanos Fernández MI, Leclercq IA, Aghayeva G, Elzouki AN, Tumi A, Sharara AI, Labidi A, Sanai FM, Matar K, Al-Mattooq M, Akroush MW, Benazzouz M, Debzi N, Alkhatry M, Barakat S, Al-Busafi SA, Rwegasha J, Yang W, Adwoa A, Opio CK, Sotoudeheian M, Wong YJ, George J, Zheng MH. Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. JHEP Rep. 2025 Mar; 7(3):101271. PMID: 39980749; PMCID: PMC11840544; DOI: 10.1016/j.jhepr.2024.101271;
     
  8. Yiannakou I, Long MT, Jacques PF, Beiser A, Pickering RT, Moore LL. Eggs, Dietary Choline, and Nonalcoholic Fatty Liver Disease in the Framingham Heart Study. J Nutr. 2025 Mar; 155(3):923-935.View Related Profiles. PMID: 39424072; PMCID: PMC11934245; DOI: 10.1016/j.tjnut.2024.10.026;
     
  9. Alanaeme CJ, Ghazi L, Akinyelure OP, Wen Y, Christenson A, Poudel B, Dooley EE, Chen L, Hardy ST, Foti K, Bowling CB, Long MT, Colantonio LD, Muntner P. Trends in the Prevalence of Multiple Chronic Conditions Among US Adults With Hypertension From 1999-2000 Through 2017-2020. Am J Hypertens. 2024 Jun 14; 37(7):493-502. PMID: 38576398; PMCID: PMC11519032; DOI: 10.1093/ajh/hpae040;
     
  10. Sun N, Prescott B, Ma J, Mohanty A, Long MT, Walker ME. Prevalence of Steatotic Liver Disease Subtypes and Association With Metabolic Risk Factors in the Framingham Heart Study. Clin Gastroenterol Hepatol. 2024 Nov; 22(11):2330-2333.View Related Profiles. PMID: 38857746
     
Showing 10 of 100 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 100 publications over 12 distinct years, with a maximum of 14 publications in 2023

YearPublications
20071
20155
20166
20178
20188
201913
202010
202111
202211
202314
20247
20256

Note: X.com has changed/limited the ability to embed tweets directly in external sites and we are investigating ways to restore that functionality in BU Profiles. In the meantime we are displaying a link to your x.com profile in the Websites section above.

Recent (within 3 months)

The habit of drinking certain drinks can cause cirrhosis

LaoDong 5/5/2025

Older

Is Fatty Liver Disease a Risk Factor for Cardiovascular Disease?

Hep 8/4/2023

Even Non-heavy Drinking May Lead to Liver Problems, Says New Study

Yahoo 12/20/2022

Even Non-heavy Drinking May Lead to Liver Problems, Says New Study

Eat this, not that 12/20/2022

Study finds non-heavy alcohol use associated with liver fibrosis

Medical Xpress 12/8/2022

Not the Usual Suspects: Don't Overlook NAFLD in Lean Patients

Medscape 8/30/2022

New Update Focuses on NAFLD in Lean People

Medscape 7/26/2022

New update focuses on NAFLD in lean people

MDedge 7/26/2022

Mixed Bag for Semaglutide in NASH-Related Compensated Cirrhosis

MedPage Today 6/27/2022

Fatigue Tied to Worse Outcomes in Patients With NASH

MedPage Today 5/9/2022

Adding Mesalamine to Corticosteroids Showed No Benefit in Patients With Severe UC

Medpage Today 4/13/2022

Study Supports Expanded Use of HCV-Infected Liver Donation

Medpage Today 4/11/2022

Review Highlights Unmet Need for More Effective Therapies in Crohn's

Medpage Today 3/16/2022

Drinking These Popular Beverages More Than Doubles Your Risk for Fatty Liver Disease

Woman's World 11/30/2021

The #1 Worst Drink for Your Liver, New Study Says

Eat This, Not That! 11/14/2021

Pan-PPAR Agonist 'Promising' for NASH Patients

MedPage Today 10/20/2021

9 Actionable Ways to Support Gender Equity in Gastroenterology

HealthCity 9/29/2021

Removing Opioids From the PASS Will Be Beneficial

Medpage Today 9/27/2021

Herbal Weight-Loss Supplement Tied to Severe Liver Damage

MedPage Today 8/17/2021

Medical Campus Promotes 13 Faculty to Associate Professor

BU Today 7/30/2021

FAST Score Can Stratify NASH Risk in Diabetics

Gastroenterology & Endoscopy News 5/25/2021

Boston Medical Center Receives Support from Gilead Sciences to Improve Care for High-Risk Patients Living with Non-Alcoholic Fatty Liver Disease

Mobile Health Times 1/12/2021

Obese Patients With NAFLD May Have Lower Cirrhosis Risk After Bariatric Surgery

Medscape 4/13/2020

Obese Patients with NAFLD May Have Lower Cirrhosis Risk after Bariatric Surgery

MD Alert 4/11/2020

NAFLD Fibrosis Confirmed to Predict Poor Outcome

MedPage Today 2/7/2020

Alcohol Use Increases Risk for Clinically Defined NAFLD

Healio 12/11/2019

Concord Doctor Receives Doris Duke Clinical Scientist Development Award

Wicked Local Concord 7/22/2019

2020 Boston University School of Medicine: Resident Research Mentor Award
2019 NASH TAG Conference: Emerging Leader in NAFLD
2016 Boston University School of Medicine: Women's Leadership Conference Selected Participant
2016 Boston University School of Medicine: Faculty Development and Diversity Grant Recipient
2015-2020 Boston University School of Medicine: NIH Loan Repayment Program Recipient
2014 Boston University School of Medicine: 3rd Place, Evans Research Day
2009 Tufts University School of Medicine: Massachusetts Medical Society Scholars Award
2009 Tufts University School of Medicine: Glasgow-Rubin Citation for Academic Achievement
2009 Tufts University School of Medicine: Phi Delta Epsilon Fraternity Award
2009 Tufts University School of Medicine: Alpha Omega Alpha
2008 Tufts University School of Medicine: Magna cum laude Scientific electronic exhibit award
2008 Tufts University School of Medicine: Ada Draper, MD Scholarship
2006-2007 Tufts University School of Medicine: Boston Albert Schweitzer Fellowship
2006-2008 Tufts University School of Medicine: USA Funds Scholarship
2004 Middlebury College: Magna cum laude

Dr. Long mentors Fellows, PhD Candidates, Residents, Medical Students and Undergraduate Students.

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Diversity Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
  • Work / Life Integration Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

85 E. Concord St
Boston MA 02118
Google Map


Long's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department